According to Anika Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.36. At the end of 2024 the company had a P/S ratio of 2.21.
Year | P/S ratio | Change |
---|---|---|
2024 | 2.21 | 11.2% |
2023 | 1.99 | -28.08% |
2022 | 2.77 | -20.94% |
2021 | 3.50 | -29.58% |
2020 | 4.97 | -23.2% |
2019 | 6.47 | 43.06% |
2018 | 4.52 | -35.07% |
2017 | 6.97 | 0.63% |
2016 | 6.93 | 12.24% |
2015 | 6.17 | 7.68% |
2014 | 5.73 | -21.1% |
2013 | 7.26 | 276.01% |
2012 | 1.93 | -6.29% |
2011 | 2.06 | 27.34% |
2010 | 1.62 | -36.55% |
2009 | 2.55 | 163.78% |
2008 | 0.9671 | -81.74% |
2007 | 5.30 | -0.55% |
2006 | 5.33 | 29.45% |
2005 | 4.11 | 15.77% |
2004 | 3.55 | -43.72% |
2003 | 6.31 | 725.65% |
2002 | 0.7648 | -13.42% |
2001 | 0.8833 |